SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-131920
Filing Date
2024-05-06
Accepted
2024-05-06 16:11:05
Documents
20
Period of Report
2024-05-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d790042d8k.htm   iXBRL 8-K 38349
2 EX-4.1 d790042dex41.htm EX-4.1 71985
3 EX-4.2 d790042dex42.htm EX-4.2 85415
4 EX-5.1 d790042dex51.htm EX-5.1 19161
5 EX-10.1 d790042dex101.htm EX-10.1 180390
9 GRAPHIC g790042dsp37.jpg GRAPHIC 11129
10 GRAPHIC g790042dsp38.jpg GRAPHIC 5500
11 GRAPHIC g790042dsp8a.jpg GRAPHIC 5744
  Complete submission text file 0001193125-24-131920.txt   651264

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA crvs-20240501.xsd EX-101.SCH 2865
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE crvs-20240501_lab.xml EX-101.LAB 17994
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE crvs-20240501_pre.xml EX-101.PRE 11271
23 EXTRACTED XBRL INSTANCE DOCUMENT d790042d8k_htm.xml XML 3642
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 24917595
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)